

Anthony C Keech

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6906063/publications.pdf>

Version: 2024-02-01

97
papers

11,023
citations

81743

39
h-index

42291

92
g-index

97
all docs

97
docs citations

97
times ranked

10668
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
2	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350.	1.6	559
3	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019, 139, 1483-1492.	1.6	533
4	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. <i>Lancet</i> , The, 2017, 390, 1962-1971.	6.3	487
5	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 941-950.	5.5	452
6	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017, 377, 633-643.	13.9	366
7	Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose: Results from the LIPID trial. <i>Diabetes Care</i> , 2003, 26, 2713-2721.	4.3	295
8	Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1780-1788.	6.3	270
9	Delayed versus Immediate Cord Clamping in Preterm Infants. <i>New England Journal of Medicine</i> , 2017, 377, 2445-2455.	13.9	228
10	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 756-766.	1.6	200
11	Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , 2018, 138, 131-140.	1.6	194
12	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet</i> , The, 2020, 396, 1637-1643.	6.3	167
13	Rationale and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. <i>American Heart Journal</i> , 2016, 173, 94-101.	1.2	158
14	Therapeutic Effects of PPAR α Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. <i>Diabetes</i> , 2013, 62, 261-272.	0.3	148
15	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. <i>Circulation</i> , 2020, 141, 616-623.	1.6	143
16	Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 521-528.	4.3	127
17	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 1069.	3.0	119
18	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2021, 42, 2765-2775.	1.0	119

#	ARTICLE	IF	CITATIONS
19	Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. <i>Clinical Endocrinology</i> , 1996, 45, 435-441.	1.2	116
20	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2961-2970.	1.2	115
21	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327,037 participants. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 36-49.	5.5	115
22	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. <i>JAMA Cardiology</i> , 2018, 3, 749.	3.0	105
23	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. <i>Stroke</i> , 2020, 51, 1546-1554.	1.0	102
24	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease. <i>Circulation</i> , 2018, 138, 712-723.	1.6	93
25	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. <i>JAMA Cardiology</i> , 2017, 2, 1385.	3.0	89
26	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 3024-3033.	4.3	85
27	Peroxisome Proliferator-Activated Receptor α Protects Capillary Pericytes in the Retina. <i>American Journal of Pathology</i> , 2014, 184, 2709-2720.	1.9	71
28	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 613.	3.0	66
29	Cognition After Lowering LDL-Cholesterol With Evolocumab. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2283-2293.	1.2	62
30	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , 2020, 141, 1600-1607.	1.6	61
31	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 952.	3.0	56
32	Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy. A cognitive study of patients enrolled in the FOURIER trial. <i>Clinical Cardiology</i> , 2017, 40, 59-65.	0.7	54
33	Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes. <i>JAMA Pediatrics</i> , 2021, 175, 1227.	3.3	54
34	HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2351-2358.	4.3	50
35	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. <i>JAMA Cardiology</i> , 2021, 6, 139.	3.0	50
36	Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease. <i>Circulation</i> , 2016, 133, 1851-1860.	1.6	48

#	ARTICLE	IF	CITATIONS
37	Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications. <i>Heart Rhythm</i> , 2017, 14, 866-874.	0.3	47
38	Nonsyndromic Thoracic Aortic Aneurysm and Dissection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 618-626.	1.2	46
39	Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab. <i>JAMA Cardiology</i> , 2019, 4, 59.	3.0	45
40	Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 310-318.	5.5	43
41	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015, 201, 499-507.	0.8	42
42	Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3638-e3649.	1.8	37
43	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.4	37
44	Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. <i>Diabetes Care</i> , 2022, 45, 701-709.	4.3	37
45	Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register. <i>Diabetes Care</i> , 2020, 43, 2257-2265.	4.3	31
46	Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>American Heart Journal</i> , 2012, 163, 508-514.	1.2	24
47	High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 93-99.	1.5	24
48	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 259-267.	1.2	24
49	Balancing the outcomes: reporting adverse events. <i>Medical Journal of Australia</i> , 2004, 181, 215-218.	0.8	23
50	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 787.	3.0	23
51	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , 2021, 42, 4821-4829.	1.0	23
52	Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPAR α -Independent Modulation of Thioredoxin-Interacting Protein. <i>Diabetes</i> , 2019, 68, 1040-1053.	0.3	22
53	Opposite associations between alanine aminotransferase and α -glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 783-793.	1.5	20
54	Subclinical valve thrombosis in transcatheter aortic valve implantation: A systematic review and meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1491-1499.e2.	0.4	20

#	ARTICLE	IF	CITATIONS
55	Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. <i>Atherosclerosis</i> , 2015, 242, 295-302.	0.4	19
56	Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)â€”Rationale and Design. <i>Frontiers in Pediatrics</i> , 2021, 9, 799125.	0.9	19
57	A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 444-455.	1.0	17
58	Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1244-1250.	4.3	16
59	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€”Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , 2018, 202, 39-48.	1.2	15
60	Suggested clinical approach for the diagnosis and management of â€”statin intoleranceâ€” with an emphasis on muscleâ€”related sideâ€”effects. <i>Internal Medicine Journal</i> , 2019, 49, 1081-1091.	0.5	15
61	Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. <i>Circulation</i> , 2021, 144, 1732-1734.	1.6	14
62	Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjectsâ€”A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial â€”. <i>Circulation Journal</i> , 2021, 85, 2063-2070.	0.7	13
63	Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 328-336.	1.1	12
64	Triglyceride-lowering trials. <i>Current Opinion in Lipidology</i> , 2017, 28, 477-487.	1.2	12
65	Attractions and barriers to Australian physicianâ€”researcher careers. <i>Internal Medicine Journal</i> , 2019, 49, 171-181.	0.5	12
66	The Relationship between Endothelial Progenitor Cell Populations and Epicardial and Microvascular Coronary Diseaseâ€”A Cellular, Angiographic and Physiologic Study. <i>PLoS ONE</i> , 2014, 9, e93980.	1.1	12
67	Shortening of telomere length by metabolic factors in diabetes: protective effects of fenofibrate. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 523-530.	1.8	11
68	Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register. <i>Diabetologia</i> , 2022, 65, 375-386.	2.9	11
69	Shortened relative leukocyte telomere length is associated with all-cause mortality in type 2 diabetes-analysis from the Hong Kong Diabetes Register. <i>Diabetes Research and Clinical Practice</i> , 2021, 173, 108649.	1.1	10
70	Novel Pressure-Regulated Deployment Strategy for Improving the Safety and Efficacy of Balloon-Expandable Transcatheter Aortic Valves. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2503-2515.	1.1	10
71	Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011382.	1.4	10
72	Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). <i>Contemporary Clinical Trials</i> , 2017, 62, 37-42.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. <i>BMJ Open</i> , 2021, 11, e044656.	0.8	8
74	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 460-466.	2.4	7
75	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. <i>Circulation</i> , 2021, 144, 249-251.	1.6	7
76	Interpreting the results of a clinical trial. <i>Medical Journal of Australia</i> , 2007, 186, 318-319.	0.8	6
77	Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108450.	1.1	6
78	Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1388-1396.	2.2	6
79	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	1.6	6
80	Transcatheter Aortic Valve Implantation (TAVI) Versus Surgical Aortic Valve Replacement for Aortic Stenosis (SAVR): A Cost-Comparison Study. <i>Heart Lung and Circulation</i> , 2021, 30, 1918-1928.	0.2	6
81	Protocol for the Stimulating β_3 -Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease. <i>BMJ Open</i> , 2021, 11, e049858.	0.8	5
82	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 480-487.	0.2	4
83	Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. <i>Diabetes Research and Clinical Practice</i> , 2018, 141, 156-167.	1.1	4
84	HDL as a Target for Glycemic Control. <i>Current Drug Targets</i> , 2017, 18, 651-673.	1.0	4
85	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. <i>Diabetes Research and Clinical Practice</i> , 2021, 179, 109000.	1.1	3
86	Putting results of a clinical trial into perspective. <i>Medical Journal of Australia</i> , 2007, 186, 368-370.	0.8	2
87	Clinical benefits of evolocumab appear less than hoped – Authors' reply. <i>Lancet</i> , 2018, 391, 934-935.	6.3	2
88	The case for extended thromboprophylaxis in medically hospitalised patients – not yet made. <i>European Journal of Preventive Cardiology</i> , 2019, , 204748731983657.	0.8	2
89	Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema. <i>Internal Medicine Journal</i> , 2020, 50, 127-128.	0.5	2
90	Selecting participants for clinical trials. <i>Medical Journal of Australia</i> , 2001, 175, 490-491.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 2021, 11, 18708.	1.6	1
92	<scp>Guidelineâ€based</scp> audit of the hospital management of heart failure with reduced ejection fraction. Internal Medicine Journal, 2023, 53, 1595-1601.	0.5	1
93	Cost-effectiveness Considerations of Cardiovascular Therapeutics. Heart Lung and Circulation, 2009, 18, 118-122.	0.2	0
94	The role of statin therapy in patients with lower vascular risk. Medical Journal of Australia, 2012, 197, 130-131.	0.8	0
95	Questioning statin therapy for older patients â€ Authors' reply. Lancet, The, 2020, 395, 1832-1833.	6.3	0
96	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. BMJ Open, 2021, 11, e044656.	0.8	0
97	Prevalence of diabetic retinopathy and reduced vision among Indigenous Australians in the nurseâ€led iDEES study in a regional primary care clinic. Internal Medicine Journal, 2021, , .	0.5	0